Large trial finds adding an ARB to an ACE-I does not help diabetic nephropathy

Abstract

While some evidence suggests that combining angiotensin converting-enzyme inhibitors (ACE-Is) and angiotensin receptor blockers (ARBs) might have clinically important benefits in some situations (particularly for patients with severe congestive heart failure [CHF]), a recent large randomized controlled trial (RCT) recently found no tangible benefit to combination therapy in patients with diabetes or arteriosclerotic cardiovascular disease without heart failure.